GSK has demonstrated robust sales growth, with a 13% increase to GBP 7.9 billion and a core operating profit up by 21% to GBP 2.5 billion, as noted by CEO Emma Walmsley in the latest earnings call.
GSK wins latest trial over Zantac cancer claims August 5, 2024 Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of ...
GSK Plc’s experimental vaccine for herpes failed in an early-stage trial, halting an effort to bring the first shot for the condition to market. While there were no safety concerns, the trial ...
GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage trial, keeping the drugmaker in the race to bring the technology to ...
Len Friedland, MD, Vice President of Scientific Affairs and Public Health, GSK, said: “We are excited to share data on the co‑administration of our RSV and shingles vaccines. Adult ...
(RTTNews) - GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY when co ...